Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
161
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Lyell Immunopharma Inc market cap is $333.87M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Lyell Immunopharma Inc 52 week high is $45.00 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Lyell Immunopharma Inc 52 week low is $7.20 as of November 20, 2026.
Lyell Immunopharma Inc stock price today is $13.80.
Lyell Immunopharma Inc stock price yesterday was $13.58.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Lyell Immunopharma Inc's P/E ratio is -1.18.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Lyell Immunopharma Inc P/B ratio is 1.7321.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Lyell Immunopharma Inc 50-day moving average is $11.04.